{"id":14121,"date":"2021-03-29T23:49:09","date_gmt":"2021-03-29T23:49:09","guid":{"rendered":"https:\/\/clinlabint.com\/?p=14121"},"modified":"2021-03-30T08:51:38","modified_gmt":"2021-03-30T08:51:38","slug":"wuxi-apptec-acquires-oxgene-to-strengthen-cell-and-gene-therapy-offerings","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/wuxi-apptec-acquires-oxgene-to-strengthen-cell-and-gene-therapy-offerings\/","title":{"rendered":"WuXi AppTec acquires OXGENE to strengthen cell and gene therapy offerings"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

WuXi AppTec acquires OXGENE to strengthen cell and gene therapy offerings<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

WuXi AppTec, a Shanghai, China-headquartered global provider of R&D- and manufacturingenabling services in the pharmaceutical, biotechnology and medical device industries, has acquired OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.<\/p>\n

<\/p>\n

OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec\u2019s cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit. WuXi ATU\u2019s integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU\u2019s first facility in Europe and will further enhance these industry-leading capabilities.<\/p>\n

Since its founding in 2011, OXGENE has offered discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions. It also provides manufacturing systems that deliver exceptional scalability. OXGENE\u2019s novel TESSA technology for adenoassociated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing simplify cell and gene therapy manufacturing while significantly reducing costs.<\/p>\n

\u201cOXGENE is proud to have invented a range of next-generation platforms that address the complexities of viral vector manufacturing for gene and cell therapies,\u201d said Dr. Ryan Cawood, Founder and Chief Executive Officer of OXGENE. \u201cWe are excited to join the team at WuXi ATU and to work together to scale up our technologies as a combined business, which will strengthen and broaden our service offerings for customers, improving by orders of magnitude the scale and cost of bringing cell and gene therapies to market. The benefits will be significant for the industry and for patients worldwide.\u201d<\/p>\n

\u201cWe are delighted to welcome OXGENE to WuXi ATU,\u201d said Dr. David Chang, Chief Executive Officer of WuXi ATU. \u201cBy combining WuXi ATU\u2019s world-class cell and gene therapy CTDMO platform with OXGENE\u2019s innovative capabilities, we will be able to provide transformative solutions for our customers. This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally.\u201d<\/p>\n<\/div><\/section>
\n